Compare AMP & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMP | NTRA |
|---|---|---|
| Founded | 1894 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3B | 44.7B |
| IPO Year | 2009 | 2015 |
| Metric | AMP | NTRA |
|---|---|---|
| Price | $562.42 | $314.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | ★ $544.91 | $259.07 |
| AVG Volume (30 Days) | 438.1K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | ★ 9.77 | 0.65 |
| EPS | ★ 21.64 | N/A |
| Revenue | ★ $18,911,000,000.00 | $210,939,000.00 |
| Revenue This Year | $1.79 | $18.08 |
| Revenue Next Year | $4.20 | $19.65 |
| P/E Ratio | $25.95 | ★ N/A |
| Revenue Growth | ★ 5.49 | N/A |
| 52 Week Low | $422.37 | $156.71 |
| 52 Week High | $572.56 | $326.03 |
| Indicator | AMP | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 68.24 | 67.71 |
| Support Level | $450.79 | $186.96 |
| Resistance Level | N/A | $326.03 |
| Average True Range (ATR) | 9.12 | 11.55 |
| MACD | -0.64 | 3.24 |
| Stochastic Oscillator | 81.22 | 87.46 |
Ameriprise Financial has evolved into a diversified financial services provider that generates roughly 65% of its operating profit from advice and wealth management. With nearly $1.2 trillion in segment assets under management and advisory at year-end 2025, and with roughly 10,600 affiliated and employee advisors, Ameriprise is one of the larger US-based wealth managers. It also boasts a reasonably large asset management franchise in Columbia Threadneedle, which boasted $678 billion in assets under management at year-end 2025. The firm's third segment is its retirement and protection services business, which sells insurance products to the firm's advisory clients. After eliminations, Ameriprise had $1.69 trillion in assets under management and advisory across segments at year-end 2025.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.